Nasdaq:SLP
Simulations Plus, Inc.
A Nasdaq-listed provider of advanced simulation tools empowering the pharmaceutical industry to innovate faster and more efficiently through predictive modeling.
Key Metrics
Investment Thesis
Bull Case
Investors might consider SLP if they believe in the long-term secular trend of digital transformation within pharma, where simulation is becoming essential rather than optional. The company's consistent revenue growth and healthy operating cash flow suggest that current losses could be strategic investments intended to capture future market share once economies of scale are realized.
Bear Case
The massive net loss of $64.7M combined with a retained earnings deficit of $34.4M presents a concerning trend that contradicts the company's recent revenue expansion, raising doubts about its unit economics. With no dividends or share repurchases to return value to shareholders and a significant portion of assets tied up in goodwill, the stock carries substantial downside risk if operational efficiency does not improve soon.
About Simulations Plus, Inc.
Simulations Plus Inc. (SLP) is a leading developer of simulation software and services that help pharmaceutical, biotechnology, and healthcare companies accelerate drug discovery and development processes. The company serves global markets in life sciences by providing computational models to optimize clinical trial design and reduce costs associated with bringing new therapies to market.
Analysis
Management Discussion
While revenue grew steadily from $59.6M in 2023 to $79.2M in 2025, reflecting strong top-line momentum driven by market adoption of simulation tools, profitability has deteriorated sharply with a net loss of $64.7M in the most recent year compared to profits in prior years. The cash flow from operations remains robust at $18.1M, which partially offsets the reported losses, suggesting the company may be investing heavily in growth initiatives or facing non-cash charges that are distorting the bottom line.
Industry Overview
The life sciences simulation industry is rapidly expanding as pharmaceutical companies face increasing pressure to lower drug development costs and shorten time-to-market. Companies like SLP are well-positioned to benefit from this shift, though they must navigate a competitive landscape that is becoming increasingly crowded with both established players and new entrants offering alternative AI-driven solutions.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $59.6M | $70.0M | $79.2M |
| Cost of Revenue | $11.6M | $26.9M | $33.0M |
| Gross Profit | $47.9M | $43.2M | $46.2M |
| Operating Expenses | $39.2M | $37.0M | $117.0M |
| Operating Income | $8.7M | $6.1M | $-70.7M |
| R&D | $4.5M | $5.8M | $6.9M |
| G&A | $34.7M | $22.4M | $20.9M |
| Marketing | — | $8.9M | $11.9M |
| Stock-Based Comp | $4.8M | $6.5M | $6.4M |
| D&A | $3.8M | $5.7M | $8.2M |
| Depreciation | $200.0K | $300.0K | $300.0K |
| Other OpEx | $0 | $0 | $77.2M |
| Non-Operating Income | $3.0M | $6.3M | $1.4M |
| Interest Income | — | — | $722.0K |
| Pre-Tax Income | $11.7M | $12.4M | $-69.4M |
| Income Tax | $1.7M | $2.5M | $-4.7M |
| Continuing Ops | $10.0M | $10.0M | $-64.7M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $10.0M | $10.0M | $-64.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $10.0M | $10.0M | $-64.7M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $130.4M | $39.3M | $51.5M |
| Cash & Equivalents | $57.5M | $10.3M | $30.9M |
| Marketable Securities | $57.9M | $9.9M | $1.5M |
| Accounts Receivable | $10.2M | $9.1M | $9.7M |
| Prepaid Expenses | $3.9M | $7.8M | $7.7M |
| Other Current Assets | $804.0K | $2.2M | $1.8M |
| Long-Term Assets | $55.7M | $157.3M | $80.4M |
| PP&E (Net) | $671.0K | $812.0K | $880.0K |
| Goodwill | $19.1M | $96.1M | $43.7M |
| Operating Leases | $1.2M | $1.0M | $407.0K |
| Other LT Assets | $34.7M | $59.4M | $35.4M |
| Total Assets | $186.1M | $196.6M | $131.9M |
| Current Liabilities | $12.0M | $12.1M | $6.7M |
| Accounts Payable | $144.0K | $602.0K | $470.0K |
| Current Leases | $442.0K | $475.0K | $206.0K |
| Deferred Revenue | $3.1M | $2.0M | $2.7M |
| Other Current Liab | $7.6M | $7.0M | $2.0M |
| Long-Term Liabilities | $4.1M | $2.1M | $410.0K |
| LT Operating Leases | $755.0K | $531.0K | $410.0K |
| Other LT Liab | $3.3M | $1.6M | $0 |
| Total Liabilities | $16.1M | $14.2M | $7.1M |
| Shareholders' Equity | $170.0M | $182.4M | $124.8M |
| Paid-In Capital | $145.0M | $152.3M | $20.0K |
| Retained Earnings | $25.2M | $30.4M | $-34.4M |
| AOCI | $-141.0K | $-251.0K | $-271.0K |
| Total L&E | $186.1M | $196.6M | $131.9M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $10.0M | $10.0M | $-64.7M |
| Non-Cash Adjustments | $15.2M | $6.8M | $84.5M |
| Working Capital Changes | $-3.3M | $-3.4M | $-1.7M |
| Cash from Operations | $21.9M | $13.3M | $18.1M |
| Capital Expenditures | $453.0K | $566.0K | $713.0K |
| Cash from Investing | $7.4M | $-54.0M | $3.6M |
| Share Buybacks | $20.0M | $0 | $0 |
| Dividends Paid | $4.8M | $4.8M | $0 |
| Cash from Financing | $-23.3M | $-6.6M | $-1.1M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $6.0M | $-47.2M | $20.5M |
| Beginning Cash | $51.6M | $57.5M | $10.3M |
| Ending Cash | $57.5M | $10.3M | $30.9M |
Frequently Asked Questions
How does Simulations Plus, Inc. make money?
The company's revenue is primarily derived from software licensing fees, professional consulting services for model development, and subscription-based access to its simulation platform. Additional streams include training programs for researchers and support contracts that ensure continuous system maintenance and data integrity for clients.
What are the main risks for SLP?
A significant risk is the heavy reliance on a concentrated customer base within the pharmaceutical sector, making the company vulnerable to budget cuts during economic downturns or industry-wide R&D spending reductions. The recent sharp decline in net income highlights potential issues with cost management or one-time charges that could threaten future profitability if not addressed. Regulatory changes affecting drug development timelines could also impact the demand for simulation services as companies adjust their strategic priorities.
What is SLP's competitive advantage?
SLP maintains a strong moat through proprietary algorithms and models that are deeply integrated into the drug discovery workflow of major pharmaceutical firms. Its deep domain expertise allows it to build highly specific simulations that generic competitors cannot easily replicate, creating high switching costs for enterprise customers. The company benefits from a first-mover advantage in niche areas like oncology and immunology modeling where few alternatives exist.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.